Skip to main content

Advertisement

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use

Article metrics

  • 856 Accesses

The British Society for Paediatric and Adolescent Rheumatology (BSPAR) Biologics Register monitors JIA patients treated with etanercept +/- methotrexate. We report duration of etanercept use and reasons for discontinuation, defined as cessation due to disease control or treatment failure; not including precautionary or temporary drug discontinuation for transient adverse events. Kaplan-Meier survival analysis was conducted with remaining patients censored at five years follow-up.

Results

From 2004–8, 434 etanercept treated JIA patients were enrolled; 68% female, 15.7% systemic arthritis, mean age at starting etanercept 11 years (2–21 years). At initiation of etanercept, 173 (40%) were also being treated with oral corticosteroids (the "steroid+" group). In 846 patient years of follow up, 83/434 patients (19.1%) discontinued etanercept for recorded reasons, 46 of whom (55%) were in the steroid+ group (table 1).

Table 1 Reasons for stopping Etanercept

Discontinuations were due to treatment inefficacy rather than treatment intolerance in the steroid+ group (p = 0.01). Of the 5 discontinuations due to infection related adverse events, 4 were in the steroid+ group. Using 5 year Kaplan-Meier analysis, 55% of all etanercept treated patients (95% confidence intervals 44.4% – 65.6%) had not experienced treatment failure. Discontinuation at 5 years was not associated with initial disease severity by physicians global assessment, systemic arthritis subtype, starting etanercept before age 10, disease onset before age 5, concurrent methotrexate use or chronic anterior uveitis.

Author information

Correspondence to TR Southwood.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Southwood, T., Cummins, C., Cotter, C. et al. Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use. Pediatr Rheumatol 6, P88 (2008) doi:10.1186/1546-0096-6-S1-P88

Download citation

Keywords

  • Etanercept
  • Juvenile Idiopathic Arthritis
  • Uveitis
  • Anterior Uveitis
  • Juvenile Idiopathic Arthritis Patient